News & Events

Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…

Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…

Results of Other Events On November 13, 2025, Pfizer Inc. (“Pfizer” or the “Company”) completed the previously announced acquisition of Metsera, Inc., a Delaware corporation (“Metsera”), pursuant to the Agreement and Plan of Merger, dated as of September 21, 2025, as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of November 7, 2025, by and among the Company, Metsera and Mayfair Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (as a…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 9, 2024, Pfizer Inc. (the "Company") announced that it is beginning the process of finding a successor for Dr. Mikael Dolsten, the Company’s Chief Scientific Officer and President, Pfizer Research & Development after his more than 15-year distinguished career with the Company. The Company has initiated an external search for a new Chief Sci…

Costs Associated with Exit or Disposal Activities In the second quarter of 2024, Pfizer announced it is launching a multi-year program to reduce our cost of goods sold. This cost reduction program (the “program”) will span multiple years, and is expected to include operational efficiencies, network structure changes, and product portfolio enhancements. Given the complexity in manufacturing and longer lead times required to make changes, this program will be a multi-phased effort. The first ph…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On July 27, 2023, Pfizer Inc. (“Pfizer” or “the Company”) announced that in consideration of planned future investments in Oncology, including the proposed acquisition of Seagen Inc., it is restructuring its Research and Development organization with Oncology as a stand-alone unit. Effective immediately, Dr. Chris Boshoff, currently Chief Developmen…

Other Events As previously disclosed, on March 12, 2023, Pfizer Inc. (“ Pfizer ”) entered into an Agreement and Plan of Merger with Seagen Inc. (“ Seagen ”), pursuant to which Pfizer will acquire Seagen through a merger (the “ Merger ”). The closing of the Merger is subject, among other things, to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “ HSR Act ”). In addition, if Pfizer and Seagen refer the Merger t…

Results of Operations and Financial Condition. As discussed in the Non-GAAP Financial Measure: Adjusted Income section of Management’s Discussion and Analysis of Financial Condition and Results of Operations in Pfizer’s 2021 Annual Report on Form 10-K, non-GAAP Adjusted income is an alternative measure of performance used by Pfizer Inc. (the “Company” or “we”) management to evaluate our overall performance as a supplement to our GAAP Reported performance measures. We use Adjusted income, cert…

Other Events As previously disclosed, on July 31, 2019, Pfizer Inc. (“Pfizer”) completed the transaction contemplated by that certain stock and asset purchase agreement, dated as of December 19, 2018, by and among Pfizer, GlaxoSmithKline plc (“GSK”) and certain other parties thereto (as amended, the “Purchase Agreement”), pursuant to which Pfizer and GSK agreed to combine their respective consumer healthcare businesses into GlaxoSmithKline Consumer Healthcare Holdings (No. 2) Limited (“CH JVC…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On December 9, 2021, the Compensation Committee of the Board of Directors of Pfizer Inc. approved changes under the Pfizer Inc. Global Performance Plan, Amended and Restated January 2021 (Bonus Plan). The purpose of the company’s Bonus Plan is to provide the company’s executive officers and other participating employees, with an opportunity to earn…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. John D. Young, Group President, Chief Business Officer, has announced his decision to retire from Pfizer Inc. (the “Company”) in early 2022. He will be stepping down as an executive officer no later than December 31, 2021, after which he will remain as an employee of the Company in an advisory role for a period of time in 2022. SIGNATURE Pursuant t…